标题:Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases
作者:Zhang, Xiangna; Xu, Ana; Lv, Jiahui; Zhang, Qiuqiong; Ran, Yingying; Wei, Chao; Wu, Jingde
作者机构:[Zhang, Xiangna; Xu, Ana; Lv, Jiahui; Zhang, Qiuqiong; Ran, Yingying; Wei, Chao; Wu, Jingde] Shandong Univ, Sch Pharmaceut Sci, Dept Med Chem, 44 West 更多
通讯作者:Wu, JD
通讯作者地址:[Wu, JD]Shandong Univ, Sch Pharmaceut Sci, Dept Med Chem, 44 West Wenhua Rd, Jinan 250012, Shandong, Peoples R China.
来源:EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
出版年:2020
卷:185
DOI:10.1016/j.ejmech.2019.111822
关键词:Inhibitors; NLRP3 inflammasome; Anti-inflammatory; Structure-activity; relationship; Pyroptosis
摘要:NLRP3 (Nod-like receptor protein 3) belongs to the NOD-like receptor family, which is activated by pathogen and damage-associated signals to form a multimeric protein complex, known as the NLRP3 inflammasome. NLRP3 inflammasome activation leads to release of proinfiammatory cytokines1L-1 beta and IL-18, thus inducing pyroptosis, a programmed cell death mechanism. Dysregulation of the NLRP3 inflammasome pathway is closely related to the development of many human diseases, such as neuroinflammation, metabolic inflammation, and immune inflammation. Emerging studies have suggested NLRP3 inflammasome as a potential drug-target for inflammatory diseases. Several small molecules have recently been identified to target the NLRP3 inflammasome pathway directly or indirectly and alleviate related disease pathology. This review summarizes recent evolving landscape of small molecule inhibitor development targeting the NLRP3 inflammasome pathway. (C) 2019 Elsevier Masson SAS. All rights reserved.
收录类别:SCOPUS;SCIE
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85074708339&doi=10.1016%2fj.ejmech.2019.111822&partnerID=40&md5=de56f118f9d71d7e91bdba87a4000707
TOP